Plasmodium falciparum merozoite surface protein 1 (MSP1): Genotyping and humoral responses to allele-specific variants

Acta Tropica

Volumn 81, Issue 1, 2002, Pages 33-46

  Ekala, Marie Thérèse ^a,b   Jouin, Hélène ^b   Lekoulou, Faustin ^a   Issifou, Saadou ^c   Mercereau Puijalon, Odile ^b   Ntoumi, Francine ^a,d  

^a CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^b INSTITUT PASTEUR   (France)

^c Centre Régional Pour Le Développement Et La Santé CREDESA SSP 01   (Benin)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Falciparum malaria; Gabon; IgG; Merozoite surface protein 1; Specific variants

Indexed keywords

IMMUNOGLOBULIN G; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIBODY;

ANTIBODY; MALARIA; PARASITE; TESTING METHOD;

ADOLESCENT; ADULT; AGE; ALLELE; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALARIA; MALE; PARASITE IMMUNITY; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; SCHIZONT; SEROPREVALENCE;

ADOLESCENT; ADULT; ALLELES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; CHILD; CHILD, PRESCHOOL; GABON; HUMANS; IMMUNOGLOBULIN G; INFANT; MALARIA, FALCIPARUM; MALE; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; TIME FACTORS; VARIATION (GENETICS);

PLASMODIUM FALCIPARUM;

EID: 0036140274     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(01)00188-7     Document Type: Article

References (38)

1. What is clinical malaria? Finding case definitions for field research in highly endemic areas
2. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66
3. Malaria, molecular and clinical aspects
4. The natural occurrence of circulating antibodies in populations of endemic malarious areas
5. A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein 1 in an area of unstable malaria in Sudan
6. Monoclonal antibody characterization of Plasmodium falciparum antigens in immune complexes formed when schizonts rupture in the presence of immune serum
7. Typing of field isolates of Plasmodium falciparum
8. Different genetic characteristics of Plasmodium falciparum isolates collected during successive clinical malaria episodes in Senegalese children
9. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses
10. The major merozoite surface protein as a malaria vaccine target
11. Levels of antibodies to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria
12. Mechanisms of defense against P. falciparum asexual blood stages in humans
13. In vivo veritas: Lessons from immunoglobulin-transfer experiments in malaria patients
14. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP1
15. Malaria transmission in a region of savanna-forrest mosaic, Haut-Ogooue, Gabon
16. In vivo and in vitro derived Palo Alto lines of Plasmodium falciparum are genetically unrelated
17. Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area
18. Human antibody responses to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived
19. Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease on infants living in an area of Liberia, West Africa, in which malaria is highly endemic
20. Target antigens for asexual malaria vaccine development
21. Fixed, epitope-specific, cytophilic antibody response to the polymorphic block2 domain of the Plasmodium falciparum merozoite surface antigen MSP-1 in humans living in a malaria-endemic area
22. The epidemiology of multiple Plasmodium falciparum infections. 5. Variation of Plasmodium falciparum msp1 block2 and msp2 allele prevalence and of infection complexity in two neighbouring Senegalese villages with different transmission conditions
23. Merozoite surface antigen 1 and 2 genotypes and resetting of Plasmodium falciparum in severe and mild malaria in Lambarene, Gabon
24. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface 1 (MSP-1)
25. Development of the human immune response against the major surface protein (gp190) of Plasmodium falciparum
26. Phase I trial of SP66 malaria vaccine in a malaria-experienced population in southeast Asia
27. Age-dependant carriage of multiple Plasmodium falciparum merozoite surface antigen 2 alleles in asymptomatic malaria infections
28. Extensive genetic diversity of Plasmodium falciparum isolates collected from patients with severe malaria in Dakar, Senegal
29. Evidence for an age-dependent pyrogenic threshold of P. alciparum parasitemia in highly endemic populations
30. Seasonal changes in the Plasmodium falciparum population in individuals and their relationship to clinical malaria: A longitudinal study in Sudanese village
31. Consequences of multiple infection with Plasmodium falciparum in an area of high endemicity
32. The epidemiology of multiple Plasmodium falciparum infections: 4. Age dependence of the multiple of Plasmodium falciparum infections and of other malariological indices in an area of high endemicity
33. A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections
34. Human malaria parasites in continuous culture
35. Bruce-Chawatt's essential malariology
36. World Malaria situation in 1993. Part II
37. A cohort study of Plasmodium falciparum diversity during the dry season in Ndiop, a Senegalese village with seasonal, mesoendemic malaria